gw9662 has been researched along with Insulinoma* in 1 studies
1 other study(ies) available for gw9662 and Insulinoma
| Article | Year |
|---|---|
Rosiglitazone stimulates the release and synthesis of insulin by enhancing GLUT-2, glucokinase and BETA2/NeuroD expression.
Peroxisome proliferator-activated receptor (PPAR)-gamma is a member of the nuclear receptor superfamily, and its ligands, the thiazolidinediones, might directly stimulate insulin release and insulin synthesis in pancreatic beta-cells. In the present study, we examined the effects of rosiglitazone (RGZ) on insulin release and synthesis in pancreatic beta-cell (INS-1). Insulin release and synthesis were stimulated by treatment with RGZ for 24h. RGZ upregulated the expressions of GLUT-2 and glucokinase (GCK). Moreover, it was found that RGZ increased the expression of BETA2/NeuroD gene which could regulate insulin gene expression. These results suggest that RGZ could stimulate the release and synthesis of insulin through the upregulation of GLUT-2, GCK, and BETA2/NeuroD gene expression. Topics: Anilides; Animals; Basic Helix-Loop-Helix Transcription Factors; Cells, Cultured; Glucokinase; Glucose; Glucose Transporter Type 2; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Insulinoma; Male; Nerve Tissue Proteins; PPAR gamma; Rats; Rats, Inbred OLETF; Rosiglitazone; Thiazolidinediones; Up-Regulation | 2008 |